Inactive Instrument

OncoSec Medical Inc Stock price Nasdaq

Equities

US68234L2079

Biotechnology & Medical Research

Sales 2021 - Sales 2022 - Capitalization 28.35M
Net income 2021 -45M Net income 2022 -34M EV / Sales 2021 -
Net cash position 2021 33.63M Net cash position 2022 1.12M EV / Sales 2022 -
P/E ratio 2021
-1.59 x
P/E ratio 2022
-0.83 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 84.57%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 13-12-31
Corporate Officer/Principal - 20-10-11
Corporate Officer/Principal - 21-02-17
More insiders
OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.
More about the company
  1. Stock
  2. Equities
  3. Stock OncoSec Medical Incorporated
  4. Stock OncoSec Medical Inc - Nasdaq